The Quote Is Not the Product
A softgel quote is not a complete product specification. It is a price built on assumptions about shell material, fill weight, carrier oil, overages, drying time, testing, packaging, and delivery. Two facilities can quote the same bottle count while describing materially different products and risk levels.
That is why a private label softgel manufacturer should be evaluated as a quality system and risk-control partner, not merely as a source of capsule capacity. The useful question is not whether a facility can make a softgel. Most commercial facilities can. The useful question is whether it can consistently make your specified softgel, prove that it did, and respond correctly when a result falls outside specification.
Suppose a 12,000-bottle launch receives one quote that is $0.25 lower per bottle. The apparent saving is $3,000. If the lower bid excludes an agreed stability study, lot-specific potency testing, retain samples, or packaging inspection, the difference is not manufacturing efficiency; it is an unpriced transfer of risk. A single investigation, retest, rework event, or delayed release can consume that $3,000 before the product reaches a customer.
A more useful calculation is:
Risk-adjusted launch cost = quoted price + omitted requirements + expected failure cost + delay cost.
The last two terms are not guesses pulled from thin air. They are the financial consequences of holding inventory, missing a retailer or marketplace date, repeating analytical work, replacing packaging, or explaining a quality problem to customers. The manufacturer that makes those risks visible is often a better value even when its unit price is higher.
Why Softgels Make Hidden Variables Expensive
Softgel manufacturing has less tolerance for vague specifications than a simple quote suggests. A finished capsule is the result of several linked controls, and a weakness in one stage can appear much later as a complaint or stability failure.
The Shell Is a Process Variable
Gelatin, fish gelatin, and vegetarian polymers such as HPMC do not behave identically on a rotary-die line. Their moisture content, elasticity, plasticizer requirements, sealing behavior, and drying profile differ. Even within one material category, ribbon thickness and shell moisture affect leakage, sticking, dissolution, and swallowing comfort.
A quote that says standard shell may conceal the most important physical decisions. If a brand promises a vegetarian product, needs a halal-compatible supply chain, or uses botanical ingredients that can challenge gelatin stability, shell selection is part of product performance—not a packaging preference. The manufacturer should state the material, source requirements, color and opacity, size, and acceptance criteria in writing.
The Fill Determines Dose Consistency
An oil-based solution is comparatively straightforward when the active is fully dissolved. A suspension containing CoQ10, botanical powders, or another particulate active requires control of particle size, viscosity, agitation, and fill uniformity. If particles settle during production, capsules filled at different points in the run may not have the same concentration.
The question is not merely whether the facility has a suspension tank. It is whether the master batch record defines how the fill is mixed, how often homogeneity is checked, how the line is kept agitated, and what happens when a sample falls outside the target range.
Oil-filled products also need an oxidation strategy. Incoming raw-material documentation is useful, but it does not replace finished-product controls. Carrier selection, oxygen exposure, storage, antioxidant use where appropriate, and agreed limits for oxidation markers should be addressed before the quote is accepted.
Drying and Storage Finish the Job
Freshly encapsulated softgels are not ready for a bottle. The shell must dry under controlled temperature and humidity, then reach a stable moisture balance. Excessive speed can contribute to sticking, deformation, or later softening; poor environmental control can create problems that are invisible at the time of shipment.
Packaging is part of that control system. A bottle, closure, induction seal, desiccant, and storage instruction should match the product’s sensitivity to heat and moisture. A lower quote that uses a cheaper packaging configuration may look attractive until capsules soften in a humid distribution environment.
The practical implication is simple: a manufacturer can satisfy the word softgel while failing to satisfy the product specification. Vetting must therefore examine how the facility controls the variables that the quote leaves unstated.
A Certificate Is a Floor, Not a Verdict
Certification language can make a supplier appear more qualified than the evidence supports. Current cGMP compliance under 21 CFR Part 111 is a baseline expectation for a US dietary supplement facility. It should mean documented procedures, material traceability, equipment control, trained personnel, batch records, quality-unit oversight, and investigations of deviations.
It does not mean the FDA approved a particular softgel. Facility registration is a legal registration requirement; dietary supplements do not receive pharmaceutical-style FDA preapproval before sale. A manufacturer that uses “FDA-approved” as a blanket marketing claim is showing either weak regulatory understanding or careless sales language.
A serious evaluation separates three types of evidence.
1. Facility Evidence
Request documentation that identifies:
- The legal entity and physical site covered by the certification
- The current audit date, scope, and expiration or renewal status
- Whether manufacturing, packaging, testing, and storage occur at the same site
- Which steps are subcontracted and how subcontractors are qualified
- How audit findings and corrective actions are closed
A certificate without a clear site and scope is difficult to interpret. If a prospective partner cannot provide a current certificate or an understandable explanation of its audit status, the risk exists before formulation begins.
2. Product Evidence
Ask for redacted examples from a comparable recent batch. A manufacturer does not need to disclose another client’s formula, but it should be able to show the structure and depth of its records.
Useful evidence includes:
- A finished-product specification with measurable acceptance limits
- A recent COA showing the lot number, test methods, quantitative results, and laboratory identity
- Identity and potency testing for the finished product, not only supplier paperwork
- Microbial and contaminant testing appropriate to the ingredients
- Oxidation testing for oil-based formulas when relevant
- Dissolution or disintegration data under the agreed method
- A stability protocol and the basis for the proposed expiration date
- Retain-sample and lot-traceability procedures
A COA that says only conforms or passes gives a brand little ability to assess the result. Numerical results, methods, and limits make the document useful for retailer reviews, marketplace submissions, and internal release decisions. If an ISO/IEC 17025-accredited laboratory is required by the target channel, that requirement should be identified before production rather than after a listing is challenged.
3. Behavior Evidence
The best quality signal is often how the manufacturer handles a difficult question. Does the quality contact answer directly? Does the technical team explain a limitation instead of promising that every formula is easy? Does the project manager document a decision and identify the person responsible for the next step?
A quality system is not proven by a claim of zero deviations. It is proven by controlled handling of deviations. A partner that can explain quarantine, root-cause analysis, corrective action, notification, and final disposition is more credible than one that simply promises a smooth run.
Normalize Every Quote Before Comparing It
Price comparisons become meaningful only after every supplier is quoting the same specification. Send each candidate a written scope and require every line to be marked as included, optional, customer-supplied, or excluded.
The scope should cover at least these areas:
- Formula and raw materials: Active forms, potencies, standardization, overages, carrier oils, excipients, allergens, country-of-origin requirements, and raw-material testing.
- Shell and physical design: Gelatin or vegetarian polymer, source restrictions, color, opacity, capsule size, imprinting, shell weight, and any enteric or delayed-release requirement.
- Fill process: Solution, suspension, or paste; target fill weight; viscosity range; particle-size controls; mixing and agitation; and oxygen-management requirements.
- Testing and release: Incoming identity, finished-product identity, potency, microbial limits, heavy metals or other contaminants, oxidation markers where relevant, dissolution, and whether testing is performed in-house or by an accredited external lab.
- Stability and expiration: Accelerated and real-time studies, pull points, storage conditions, retain samples, and who owns the data supporting the expiration date.
- Packaging: Bottle or blister format, closure, induction seal, desiccant, label application, lot and expiration printing, cartons, case packs, and artwork review.
- Schedule and logistics: What starts the lead time, whether raw-material procurement is included, sample approval dates, MOQ, freight, storage, partial shipments, and the treatment of delays.
- Responsibility for exceptions: Who pays for retesting, rework, rejected raw materials, failed lots, packaging errors, recalls, and approved changes.
Two quotes can differ by $0.40 per bottle because one assumes bovine gelatin and the other assumes HPMC. That is not necessarily a margin difference; it is a shell-material decision. Another pair can differ because one includes finished-product quantitative testing while the other relies largely on supplier COAs. That is a risk-allocation difference.
Lead time needs the same scrutiny. Eight weeks from purchase order is not the same as eight weeks from approved artwork, completed formula, and receipt of all raw materials. A quote with a short headline timeline may simply move the waiting period outside the quoted schedule.
The goal is not to force every facility into one cost structure. The goal is to make the assumptions visible enough that a lower number can be judged fairly.
Three Pre-Contract Tests Reveal More Than a Sales Presentation
The Documentation Test
Before paying a deposit, request a small, specific document set:
- Current cGMP certification and audit scope
- A redacted COA from a comparable softgel product
- A sample product specification or acceptance sheet
- A redacted batch record or explanation of in-process checks
- The stability protocol used for similar formulas
- The written path for complaints, deviations, and recalls
The response itself is evidence. Strong responses arrive with clear ownership, relevant examples, and limits that can be understood. Weak responses substitute brochures, generic quality statements, or a promise that documents will be available after the order.
A brand should not demand another customer’s confidential formula. It should demand enough documentation to determine whether the proposed partner records the variables that matter.
The Technical Test
Send the same one-page brief to every shortlisted facility. Include the active ingredients, target dose, intended shell material, expected annual volume, target market, packaging format, and required launch date. Ask the manufacturer to explain:
- Why the proposed shell and carrier are compatible with the formula
- Whether the fill is a solution, suspension, or paste and what that implies for uniformity
- Which process variables require in-process monitoring
- Which tests will be performed on each finished lot
- How stability will be established
- What pilot samples or approval checkpoints are needed
- Which assumptions could change the MOQ, lead time, or price
A CoQ10 suspension or an oxidation-sensitive omega-3 formula is a useful stress test because it requires more than a catalog formula and a bottle label. A technically serious manufacturer may recommend a different shell, carrier, or testing plan. That is a positive signal when the recommendation is explained and documented.
A sales-only response usually jumps directly to MOQ and unit price. It may be efficient, but it does not demonstrate that the facility has understood the formulation risk.
The Accountability Test
Ask a hypothetical question that forces the manufacturer to describe its quality culture:
If finished-product potency is outside specification, or capsules begin sticking after drying, what happens next, who is notified, who pays for the investigation, and who decides whether the lot can be released?
A credible answer should include quarantine, an out-of-specification investigation, review of batch and laboratory records, root-cause analysis, corrective action, documented disposition, and brand notification. Retesting should follow an approved procedure; it should not mean repeatedly testing until a passing result appears.
Ask the same type of question about raw-material substitutions, packaging changes, missed milestones, and customer complaints. A partner that cannot explain decision rights before production is unlikely to become more organized after money and inventory are committed.
Use a Scorecard, Then Enforce Hard Gates
A weighted scorecard keeps a persuasive salesperson or a low quote from dominating the decision. For a risk-sensitive launch, an example weighting is:
- 30% quality evidence: cGMP documentation, batch controls, COAs, testing depth, stability support, and release authority
- 25% technical fit: Shell and fill expertise, formulation response, equipment, and compatibility reasoning
- 15% traceability and change control: Lot records, material qualification, substitutions, deviations, and recall readiness
- 15% execution: Project ownership, communication, sampling, schedule discipline, and problem escalation
- 10% market documentation: Certifications and laboratory capabilities required by the intended channel
- 5% normalized price: Total cost after all required services and risk controls are included
Score each category from zero to five and write the evidence beside the score. A score without a document, answer, or observed process is an opinion.
Some conditions should be hard gates rather than weighted factors:
- No current certification or unclear site identity
- Refusal to provide a meaningful sample COA
- No explanation of which tests are performed on every lot
- Undisclosed subcontracting
- No written change-control process
- Ambiguous formula, specification, or intellectual-property ownership
- Refusal of a reasonable audit or live facility walkthrough
- A contract that allows material or process substitutions without written approval
A supplier should not remain on the shortlist because an attractive price offsets a hard failure. Weighted scoring is useful for choosing among qualified partners, not for rationalizing an unqualified one.
Put the Risk Controls in the Manufacturing Agreement
A thorough evaluation loses value if the contract reduces every promise to a vague service description. The agreement should preserve the evidence and controls used during vetting.
At minimum, define:
- The approved formula, active forms, potency ranges, shell material, fill weight, and physical specifications
- The testing panel, methods, acceptance limits, laboratory responsibilities, and COA format
- The procedure for approving samples and the conditions that constitute acceptance
- Written notice and approval requirements for raw-material, formula, shell, process, laboratory, or packaging changes
- Stability responsibilities and the basis for expiration dating
- Retain-sample duration and access to batch, test, and traceability records
- Treatment of nonconforming lots, retesting, rework, credits, replacement, and schedule impact
- Manufacturing milestones and the point from which lead time is measured
- Ownership of custom formulations, specifications, artwork, tooling, and project data
- Disclosure and approval of subcontractors
- Recall cooperation, insurance coverage, and responsibility for documented manufacturing defects
Formula ownership deserves special attention in private label work. A stock formula, semi-custom formula, and exclusive custom formula are not interchangeable. The agreement should state what the brand can take to another facility, what the manufacturer may sell to other clients, and which data belongs to each party.
Verbal assurances about exclusivity or testing are difficult to enforce after a batch problem. Written specifications convert a sales promise into an operating requirement.
When the Lower Quote Is Actually Better
A lower price is not automatically a warning sign. It can reflect higher line utilization, simpler packaging, better raw-material purchasing, lower freight, or a standardized process that genuinely costs less. The issue is comparability.
The lower quote deserves serious consideration when both suppliers offer the same:
- Formula and shell
- Fill weight and physical design
- Testing and release requirements
- Stability support
- Packaging configuration
- Lead-time definition
- Documentation and retain-sample access
- Responsibility for deviations and failed lots
If those terms match and one facility can show equal or stronger process evidence, lower cost is a legitimate advantage. If the terms do not match, the price difference cannot be interpreted yet.
A useful request is: “Please identify every assumption that makes this quote lower than the alternative.” The answer may reveal a harmless efficiency—or a missing control that would have been discovered only after the purchase order.
The Decisive Question
The strongest manufacturing partner is not the one that promises that nothing will go wrong. It is the one that makes uncertainty visible early, assigns each risk to an owner, and shows how the batch will be controlled when reality differs from the plan.
The right question is not, “Who can make this softgel cheapest?” It is, “Who can show how this product stays within specification—and what happens when it does not?”
A trustworthy quote is the final expression of a clear specification, a documented quality system, and an agreed response to failure. Until those pieces are visible, the lowest number is not a bargain. It is simply the least complete description of what the launch may cost.